Wire flash
HealthFDA approves Revolution Medicines' pancreatic cancer drug Rasonque, doubling survival time vs chemo
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
The U.S. Food and Drug Administration has approved daraxonrasib, a new once-daily pill for pancreatic cancer, sold under the brand name Rasonque by Revolution Medicines. The drug, which blocks RAS proteins, was shown in trials to double patient survival time compared to standard chemotherapy. Approved six months ahead of schedule, it joins a short list of treatment options for pancreatic cancer, the fourth leading cause of cancer deaths in the United States. The approval marks a significant advancement for one of the deadliest cancer types.
Source report
Topline
The Food and Drug Administration has approved a new medication for pancreatic cancer patients called daraxonrasib. This once-daily pill blocks RAS proteins and has been shown to double patient survival time when compared to standard chemotherapy treatment.
Key Facts
- The medication, manufactured by the biotech company Revolution Medicines, is sold under the brand name Rasonque.
- It was approved six months ahead of schedule on Wednesday.
- Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, and Rasonque is one of the few treatment options available.
This is a developing story and will be updated.
Source
Forbes - BusinessWestern
Part of this Story
FDA Approves Revolution Medicines' Pancreatic Cancer Pill Rasonque, Doubling Survival